3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Fallopian Tube Neoplasms
10
Ovarian Neoplasms
7
Endometrial Neoplasms
5
Breast Neoplasms
4
Prostatic Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Triple Negative Breast Neoplasms
2
Osteosarcoma
2
Neuroendocrine Tumors
2
Neuroblastoma
2
Neoplasms
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Glioma
2
Ependymoma
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Recurrence
1
Interventions
Temozolomide
18
Radiation
7
Magnetic Resonance Spectroscopy
7
Radiotherapy
6
Specimen Handling
4
Lomustine
4
Bevacizumab
4
Aminolevulinic Acid
3
veliparib
2
trametinib
2
lutetium Lu 177 dotatate
2
dabrafenib
2
azeliragon
2
Surgical Procedures, Operative
2
Receptors, Interleukin-8B
2
Nivolumab
2
D2C7-(scdsFv)-PE38KDEL
2
Carboplatin
2
Biopsy
2
varlilumab
1
ulixertinib
1
tinostamustine
1
selinexor
1
ruxolitinib
1
ribociclib
1
relatlimab
1
regorafenib
1
peposertib
1
pembrolizumab
1
olaparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
olaparib
×
30 days
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled